Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
UBS
Chubb
US Army
Moodys
Baxter
Covington
Medtronic
Colorcon
Dow

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077067

« Back to Dashboard
NDA 077067 describes NIMODIPINE, which is a drug marketed by Thepharmanetwork Llc, Heritage Pharms Inc, Sofgen Pharms, Bionpharma Inc, and Sun Pharm Inds Inc, and is included in five NDAs. It is available from nine suppliers. Additional details are available on the NIMODIPINE profile page.

The generic ingredient in NIMODIPINE is nimodipine. There are seven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the nimodipine profile page.

Summary for NDA: 077067

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 077067

Ingredient-typeDihydropyridines
Mechanism of ActionCalcium Channel Antagonists

Suppliers and Packaging for NDA: 077067

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NIMODIPINE
nimodipine
CAPSULE;ORAL 077067 ANDA Cardinal Health 55154-4560 55154-4560-0 10 BLISTER PACK in 1 BAG (55154-4560-0) > 1 CAPSULE in 1 BLISTER PACK
NIMODIPINE
nimodipine
CAPSULE;ORAL 077067 ANDA Caraco Pharmaceutical Laboratories, Ltd. 57664-135 57664-135-64 30 BLISTER PACK in 1 CARTON (57664-135-64) > 1 CAPSULE in 1 BLISTER PACK (57664-135-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength30MG
Approval Date:Apr 17, 2007TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Baxter
Argus Health
Merck
Fish and Richardson
Daiichi Sankyo
McKinsey
Chinese Patent Office
AstraZeneca
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot